Jpmorgan Chase & CO Prelude Therapeutics Inc Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 23,780 shares of PRLD stock, worth $29,962. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,780
Previous 61,149 61.11%
Holding current value
$29,962
Previous $77,000 76.62%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$0.64 - $1.39 $23,916 - $51,942
-37,369 Reduced 61.11%
23,780 $18,000
Q4 2024

Feb 12, 2025
BUY
$0.8 - $2.04 $44,146 - $112,573
55,183 Added 924.96%
61,149 $77,000
Q3 2024

Dec 26, 2024
BUY
$2.07 - $6.37 $219 - $675
106 Added 1.81%
5,966 $12,000
Q3 2024

Nov 08, 2024
BUY
$2.07 - $6.37 $219 - $675
106 Added 1.81%
5,966 $12,000
Q2 2024

Dec 26, 2024
SELL
$3.32 - $5.63 $351 - $596
-106 Reduced 1.78%
5,860 $22,000
Q2 2024

Aug 12, 2024
SELL
$3.32 - $5.63 $1,284 - $2,178
-387 Reduced 6.19%
5,860 $22,000
Q1 2024

Dec 26, 2024
BUY
$2.68 - $4.84 $753 - $1,360
281 Added 4.71%
6,247 $29,000
Q1 2024

May 10, 2024
SELL
$2.68 - $4.84 $8,396 - $15,163
-3,133 Reduced 33.4%
6,247 $29,000
Q4 2023

Dec 26, 2024
BUY
$1.69 - $4.37 $5,769 - $14,919
3,414 Added 57.22%
9,380 $40,000
Q4 2023

Feb 12, 2024
SELL
$1.69 - $4.37 $13,474 - $34,842
-7,973 Reduced 45.95%
9,380 $40,000
Q3 2023

Nov 14, 2023
BUY
$2.74 - $4.79 $21,958 - $38,387
8,014 Added 85.81%
17,353 $53,000
Q2 2023

Aug 11, 2023
BUY
$4.45 - $8.12 $35,355 - $64,513
7,945 Added 569.94%
9,339 $42,000
Q1 2023

May 11, 2023
BUY
$4.58 - $7.34 $444 - $711
97 Added 7.48%
1,394 $7,000
Q4 2022

Feb 13, 2023
SELL
$4.61 - $8.5 $5,319 - $9,809
-1,154 Reduced 47.08%
1,297 $8,000
Q3 2022

Nov 14, 2022
BUY
$5.0 - $8.82 $2,090 - $3,686
418 Added 20.56%
2,451 $16,000
Q2 2022

Aug 11, 2022
SELL
$4.0 - $7.55 $28,924 - $54,594
-7,231 Reduced 78.05%
2,033 $11,000
Q1 2022

May 11, 2022
BUY
$6.9 - $13.22 $14,076 - $26,968
2,040 Added 28.24%
9,264 $64,000
Q4 2021

Feb 10, 2022
BUY
$11.89 - $31.74 $2,437 - $6,506
205 Added 2.92%
7,224 $91,000
Q3 2021

Nov 12, 2021
BUY
$25.78 - $38.65 $180,949 - $271,284
7,019 New
7,019 $220,000

Others Institutions Holding PRLD

# of Institutions
50
Shares Held
27.9M
Call Options Held
0
Put Options Held
0
View Full List

About Prelude Therapeutics Inc

PRLD Quotes by TradingView
  • Ticker PRLD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,369,200
  • Market Cap $45.8M
  • Description
  • Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...
More about PRLD
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email